Archon Biosciences is a biotech company pioneering computationally designed ‘Antibody Cages’ to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly manufacture Antibody Cages (AbCs), a new class of biologics with unique potency and differentiated biodistribution. AbCs integrate the binding affinity and specificity of antibodies into […]
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company’s multispecific antibodies are designed to harness and direct the power of both innate and adaptive immune systems, providing a safer and more precise alternative to conventional CD3-based therapies. This is made possible by targeting a unique […]
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and sensitive. Current techniques for measuring changes in protein synthesis and degradation often fall short in sensitivity and simplicity, limiting scientists’ ability to fully understand disease […]
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built on cutting-edge research from the research group of Professor Axel Behrens at the Institute of Cancer Research in the UK, which has identified a range of novel targets and mechanisms […]
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As more individuals choose to start families later in life, the demand for effective fertility treatments has never been higher. U-Ploid Biotechnologies is a venture-backed startup on a mission to transform […]
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections. BioTryp’s technology targets bacteria’s key defense mechanism, offering an alternative to traditional antibiotic treatments. The company’s small molecules are designed to block the communication process that […]
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and autoimmune diseases. Bastion’s GRIT™ (Genetically Reconfigured & Improved Treg) platform technology utilises genetic engineering to restore and enhance the patient’s Treg function while also targeting Tregs to specific sites of […]
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new class of genomic medicines that selectively block oncogene translation in hard-to-treat tumors. The company is led by a team whose work has generated 12 registered therapeutics, and founded by pioneers […]
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company’s technology holds potential for developing gene therapies for brain diseases. Couragene’s proprietary STEP (Stimuli-responsive Traceless Engineering Platform) technology was developed to leverage chemical engineering approaches to enable efficient intracellular delivery of genetic medicine payloads, […]
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring gene function, Function Oncology aims to identify optimal therapeutic opportunities for patients and advance the next generation of targeted cancer therapies. Function Oncology’s functional genomics […]
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an immune modulator by Mallia co-founder Prof. Dr. Alexander Steinkasserer in 2001, is a naturally occurring soluble form of the human CD83 protein CD83. sCD83 has an immune-modulatory function and induces […]
T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases. Founded in 2022, the company is based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine. Professor Allan Bradley has previously founded several companies including Kymab, a company developing fully human monoclonal antibodies […]
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal and plant genomes, Empyrean is working to enhance and modulate neuroactive compounds produced by these kingdoms. Launched in 2022, the company’s platform is being used […]
EnPlusOne Biosciences aims to bring a versatile, sustainable, and scalable RNA synthesis technology to market to unlock development of new RNA drugs, vaccines, and gene-editing therapies. The company’s advanced-stage technology has more than six years of development at the Wyss Institute at Harvard University, and is co-founded by Dr. George Church of Harvard Medical School. […]
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ is a non-viral microfluidic platform for highly effective delivery of external cargos such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator™ technology enables high […]
Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class of medicines that combine the advantages of traditional small-molecule drugs and larger protein therapeutics. In a paper published in Cell in September 2022 titled “Accurate […]
CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not the genome of a healthy cell thereby conferring target selectivity. It is uniquely directed towards knocking out genetic pathways to allow for a broad-based combinatorial […]
THERAtRAME was founded based on new insights in transfer RNA (tRNA) epitranscriptomics resulting from over a decade of fundamental research at the GIGA Institute (ULiège) and WELBIO. Transfer RNAs mediate the translation of the genetic information (mRNAs) into cellular effectors (proteins). Chemical modifications of tRNA molecules promote cellular adaptation through reprogramming of protein expression, playing […]
NEOsphere Biotechnologies is a German biotech startup that has developed a proteomic platform for systematic identification of novel targets for targeted protein degradation. NEOsphere uses cutting-edge mass spectrometry technology to screen libraries of tens of thousands of compounds against proteomes of more than 10,000 proteins. Using purpose-built data processing the company systematically extracts high-probability candidates […]
Founded in 2021, Epigenic Therapeutics is a Chinese startup developing next generation gene editing therapies for a wide variety of diseases, using modulation of the epigenetic genome. Epigenic Therapeutics’ proprietary technology platform employs artificial intelligence algorithms to explore and obtain an optimized CRISPR-Cas component to regulate target gene(s) or govern the expression of one or […]